InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of InflaRx (NASDAQ:IFRX) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $6.00 price target on the stock.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of InflaRx from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Leerink Partnrs downgraded shares of InflaRx from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 3rd. Leerink Partners restated a “market perform” rating and set a $2.00 price target (down from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a report on Monday, December 22nd. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

InflaRx Stock Performance

NASDAQ IFRX opened at $1.02 on Tuesday. The stock has a fifty day simple moving average of $1.21 and a 200-day simple moving average of $1.13. The stock has a market cap of $68.47 million, a PE ratio of -1.50 and a beta of 1.46. InflaRx has a twelve month low of $0.71 and a twelve month high of $2.77.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. Research analysts predict that InflaRx will post -1.04 EPS for the current year.

Institutional Trading of InflaRx

Several hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC grew its holdings in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after acquiring an additional 7,616 shares in the last quarter. Concurrent Investment Advisors LLC acquired a new position in shares of InflaRx during the second quarter worth $65,000. Susquehanna International Group LLP acquired a new position in shares of InflaRx during the third quarter worth $190,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in InflaRx by 158.3% in the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock valued at $118,000 after buying an additional 91,927 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in InflaRx in the third quarter valued at $214,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.